Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Website: recursion.com


  • Bad financial results growth rate -34.6% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (43.5%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -14.6% (LTM)
  • Share price is 43.1% higher than minimum and 73.9% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)
  • For the last 3 months insiders sold company shares on $0.6 mln (-0.030% of cap.)

Key Financials (Download financials)

Ticker: RXRX
Share price, USD:  (+6.9%)4.05
year average price 4.04  


year start price 5.87 2025-10-29

max close price 5.87 2025-10-29

min close price 2.83 2026-05-19

current price 4.05 2026-10-28
Common stocks: 532 460 085

Dividend Yield:  0.0%
EV / Sales: 18.4x
Margin (EBITDA LTM / Revenue): -511.9%

Target EV / EBITDA (hist percentile): 30.0x
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 2 023
Net Debt ($m): -479
EV (Enterprise Value): 1 544
EBITDA LTM (млн $): -430
Price to Book: 1.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-02-07fool.com

This $4 Stock Could Be Your Ticket to Millionaire Status

2026-02-04zacks.com

Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights

2026-01-29zacks.com

Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors

2026-01-23zacks.com

Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors

2026-01-22seekingalpha.com

Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript

2026-01-15zacks.com

Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note

2026-01-13seekingalpha.com

Recursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-12-08reuters.com

Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial

2025-11-21seekingalpha.com

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

2025-11-18seekingalpha.com

Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol RXRX RXRX RXRX RXRX RXRX RXRX RXRX RXRX RXRX RXRX RXRX RXRX RXRX RXRX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-05 2025-08-05 2024-11-06 2024-08-08 2024-05-09 2023-11-09 2023-08-08 2023-05-08 2022-11-08
acceptedDate 2025-11-05 06:40:25 2025-08-05 06:33:05 2025-02-28 06:33:59 2024-11-06 16:18:48 2024-08-08 08:09:26 2024-05-09 16:11:55 2024-02-29 08:25:26 2023-11-09 08:08:57 2023-08-08 08:08:07 2023-05-08 08:22:37 2023-02-27 16:44:03 2022-11-08 16:35:39 2022-03-23 08:01:20 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 5M 19M 59M 26M 14M 14M 44M 10M 11M 12M 40M 13M 10M 3M
costOfRevenue 30M 20M 45M 12M 13M 15M 43M 11M 9M 12M 48M 15M 0 0
grossProfit -24M -1M 14M 14M 1M -772 000 1M -775 000 2M -314 000 -9M -2M 10M 3M
grossProfitRatio -4.718 -0.055 0.537 0.091 -0.056 -0.077 0.148 -0.026 -0.18
researchAndDevelopmentExpenses 121M 129M 314M 75M 70M 64M 241M 70M 55M 47M 156M 41M 135M 63M
generalAndAdministrativeExpenses 42M 47M 178M 38M 32M 31M 111M 29M 28M 23M 82M 19M 58M 25M
sellingAndMarketingExpenses 0 0 0 0 0 108 000 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 42M 47M 178M 38M 32M 31M 111M 29M 28M 23M 82M 19M 58M 25M
otherExpenses -15M -120 000 0 0 -392 000 160 000 -699 000 2M 5M -103 000 -162 000 -107 000 -178 000 -549 000
operatingExpenses 148M 175M 493M 112M 102M 96M 351M 99M 83M 70M 237M 60M 193M 88M
costAndExpenses 177M 195M 538M 124M 115M 110M 394M 110M 93M 82M 285M 76M 193M 88M
interestIncome 0 5M 16M 4M 3M 4M 19M 5M 5M 5M 6M 2M 73 000 336 000
interestExpense 0 480 000 2M 553 000 394 000 20 000 97 000 25 000 26 000 19 000 55 000 13 000 3M 1M
depreciationAndAmortization 21M 24M 36M 7M 8M 7M 24M 8M 6M 8M 12M 5M 8M 4M
ebitda -141M -148M -427M -88M -90M -89M -308M -85M -82M -62M -228M -57M -175M -82M
ebitdaratio -27.286 -7.725 -3.371 -6.419 -6.448 -8.455 -7.418 -5.075 -4.401
operatingIncome -172M -176M -479M -98M -101M -96M -350M -100M -82M -70M -246M -63M -183M -85M
operatingIncomeRatio -33.276 -9.225 -3.771 -6.974 -6.984 -9.854 -7.418 -5.758 -4.794
totalOtherIncomeExpensesNet 10M 4M 14M 3M 2M 4M 18M 2M 5M 5M 6M 2M -4M -2M
incomeBeforeTax -162M -172M -465M -96M -98M -92M -332M -93M -77M -65M -239M -60M -186M -87M
incomeBeforeTaxRatio -31.353 -8.998 -3.668 -6.802 -6.681 -9.208 -6.965 -5.384 -4.631
incomeTaxExpense 3000 0 -1M 167 000 -523 000 -779 000 -4M 2M -6M -5M 0 -2M 0 0
netIncome -162M -172M -464M -96M -98M -91M -328M -93M -77M -61M -239M -58M -186M -87M
netIncomeRatio -31.353 -8.998 -3.668 -6.766 -6.624 -9.208 -6.965 -5.01 -4.468
eps -0.36 -0.41 -1.69 -0.34 -0.4 -0.39 -1.58 -0.43 -0.38 -0.32 -1.36 -0.34 -1.05 -0.525
epsdiluted -0.36 -0.41 -0.34 -0.4 -0.39 -0.43 -0.38 -0.32 -0.34
weightedAverageShsOut 447M 417M 274M 283M 242M 236M 208M 214M 201M 192M 176M 173M 170M 166M
weightedAverageShsOutDil 447M 417M 274M 283M 242M 236M 208M 214M 201M 192M 176M 173M 170M 166M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-29 2023-02-27 2022-03-23 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 14M 19M 6M -3M -1M
ebit -463M -332M -239M -184M -86M
nonOperatingIncomeExcludingInterest -16M -18M -6M 752 000 1M
netIncomeFromContinuingOperations -464M -328M -239M -186M -87M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -464M -328M -239M -186M -87M
epsDiluted -1.69 -1.58 -1.36 -1.05 -0.525

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol RXRX RXRX RXRX RXRX RXRX RXRX RXRX RXRX RXRX RXRX RXRX RXRX RXRX RXRX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-05 2025-08-05 2024-11-06 2024-08-08 2024-05-09 2023-11-09 2023-08-08 2023-05-08 2022-11-08
acceptedDate 2025-11-05 06:40:25 2025-08-05 06:33:05 2025-02-28 06:33:59 2024-11-06 16:18:48 2024-08-08 08:09:26 2024-05-09 16:11:55 2024-02-29 08:25:26 2023-11-09 08:08:57 2023-08-08 08:08:07 2023-05-08 08:22:37 2023-02-27 16:44:03 2022-11-08 16:35:39 2022-03-23 08:01:20 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 660M 528M 594M 428M 476M 300M 392M 387M 406M 473M 550M 455M 285M 262M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 231M 0
cashAndShortTermInvestments 660M 528M 594M 428M 476M 300M 392M 387M 406M 473M 550M 455M 517M 262M
netReceivables 22M 22M 49M 2M 3M 3M 3M 3M 3M 2M 3M 12M 9M 156 000
inventory 0 0 0 0 0 0 0 2M 3M 1M 0 0 0 0
otherCurrentAssets 32M 37M 71M 44M 46M 41M 43M 18M 19M 16M 17M 13M 9M 4M
totalCurrentAssets 714M 587M 714M 474M 522M 344M 438M 411M 431M 492M 570M 482M 535M 266M
propertyPlantEquipmentNet 181M 194M 233M 159M 156M 122M 120M 120M 125M 125M 121M 120M 65M 26M
goodwill 162M 164M 149M 52M 52M 52M 52M 53M 61M 801 000 801 000 801 000 801 000 801 000
intangibleAssets 322M 341M 336M 34M 38M 33M 36M 39M 43M 1M 1M 1M 1M 2M
goodwillAndIntangibleAssets 484M 506M 485M 86M 90M 85M 88M 92M 103M 2M 2M 2M 2M 2M
longTermInvestments 0 6M 6M 0 7M 7M 0 8M 8M 0 0 0 0 0
taxAssets 957 000 957 000 2M 0 0 -1 0 -8M -8M 0 0 0 0 0
otherNonCurrentAssets 19M 9M 9M 7M 308 000 254 000 7M 8M 8M 8M 8M 8M 9M 4M
totalNonCurrentAssets 685M 715M 734M 252M 253M 214M 216M 220M 236M 135M 131M 130M 76M 32M
otherAssets 0 0 0 0 0 1 0 0 0 0 0 0 0 0
totalAssets 1 400M 1 302M 1 449M 726M 776M 558M 654M 631M 667M 627M 701M 612M 610M 299M
accountPayables 14M 19M 22M 2M 4M 5M 4M 4M 2M 4M 5M 4M 3M 1M
shortTermDebt 20M 20M 22M 16M 25M 6M 41 000 6M 6M 5M 97 000 6M 90 000 1M
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 278 000
deferredRevenue 47M 40M 62M 50M 32M 37M 36M 44M 73M 58M 57M 47M 10M 10M
otherCurrentLiabilities 73M 85M 82M 41M 25M 26M 24M 40M 33M 25M 20M 27M 12M 3M
totalCurrentLiabilities 155M 164M 187M 109M 86M 74M 93M 94M 114M 92M 100M 83M 47M 23M
longTermDebt 62M 68M 19M 74M 73M 1M 1M 45M 47M 48M 536 000 47M 633 000 11M
deferredRevenueNonCurrent 0 126M 119M 0 29M 37M 51M 51M 32M 57M 70M 94M 7M 17M
deferredTaxLiabilitiesNonCurrent 23M 24M 17M 168 000 21M 528 000 1M 2M 4M 0 0 0 0 0
otherNonCurrentLiabilities 112M 2M 5M 19M 3M 44M 0 0 0 0 0 84M 4M 451M
totalNonCurrentLiabilities 197M 219M 226M 93M 105M 83M 97M 99M 84M 105M 115M 140M 21M 482M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 65M 67M 62M 59M 44M 50M 50M 51M 51M 50M 52M 11M 3M
totalLiabilities 353M 383M 414M 202M 191M 157M 190M 193M 198M 197M 215M 223M 67M 505M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 5000 4000 4000 3000 3000 2000 2000 2000 2000 2000 2000 2000 2000 0
retainedEarnings -1 968M -1 806M -1 431M -1 252M -1 157M -1 059M -968M -875M -782M -705M -640M -582M -400M -214M
accumulatedOtherComprehensiveIncomeLoss 34M 44M -8M 0 0 0 0 0 0 0 0 0 -126 000 0
othertotalStockholdersEquity 2 981M 2 681M 1 777M 1 741M 1 460M 1 313M 1 251M 1 135M 970M
totalStockholdersEquity 1 047M 919M 1 035M 525M 584M 401M 463M 438M 469M 430M 486M 388M 543M -206M
totalEquity 1 047M 919M 1 035M 525M 584M 401M 463M 438M 469M 430M 486M 388M 543M -206M
totalLiabilitiesAndStockholdersEquity 1 400M 1 302M 726M 776M 558M 631M 667M 627M 612M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 400M 1 302M 1 449M 726M 776M 558M 654M 631M 667M 627M 701M 612M 610M 299M
totalInvestments 0 6M 6M 0 7M 7M 0 8M 8M 0 0 0 231M 0
totalDebt 82M 88M 108M 91M 90M 51M 51M 51M 53M 53M 51M 52M 11M 16M
netDebt -577M -440M -486M -337M -386M -249M -341M -336M -353M -420M -499M -402M -274M -246M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-29 2023-02-27 2022-03-23 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 0 0 0 34 000 156 000
otherReceivables 49M 3M 3M 9M 0
prepaids 0 0 0 0 0
totalPayables 22M 4M 5M 3M 1M
otherPayables 0 0 0 0 0
accruedExpenses 0 23M 12M 21M 7M
capitalLeaseObligationsCurrent 0 6M 6M 1M 467 000
capitalLeaseObligationsNonCurrent 67M 43M 44M 9M 3M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 2 474M 1 431M 1 125M 943M 7M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol RXRX RXRX RXRX RXRX RXRX RXRX RXRX RXRX RXRX RXRX RXRX RXRX RXRX RXRX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-05 2025-08-05 2024-11-06 2024-08-08 2024-05-09 2023-11-09 2023-08-08 2023-05-08 2022-11-08
acceptedDate 2025-11-05 06:40:25 2025-08-05 06:33:05 2025-02-28 06:33:59 2024-11-06 16:18:48 2024-08-08 08:09:26 2024-05-09 16:11:55 2024-02-29 08:25:26 2023-11-09 08:08:57 2023-08-08 08:08:07 2023-05-08 08:22:37 2023-02-27 16:44:03 2022-11-08 16:35:39 2022-03-23 08:01:20 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -162M -172M -464M -96M -98M -91M -328M -93M -77M -65M -239M -60M -186M -87M
depreciationAndAmortization 21M 24M 36M 7M 8M 7M 24M 8M 6M 4M 12M 3M 8M 4M
deferredIncomeTax 0 0 0 0 0 0 0 19 000 0 0 0 0 827 000 0
stockBasedCompensation 25M 26M 82M 18M 17M 16M 54M 17M 12M 9M 28M 9M 15M 4M
changeInWorkingCapital -26M 35M -38M 47M -10M -36M -50M -4M -10M -24M 105M -8M -306 000 31M
accountsReceivables 4M 25M -6M 304 000 736 000 -1M 0 -203 000 -814 000 0 -2000 0 114 000 -1M
inventory 0 0 0 0 0 0 0 203 000 814 000 0 0 0 8M 0
accountsPayables -6M -5M 6M -2M -1M 1M -987 000 2M -3M -339 000 2M 714 000 2M -185 000
otherWorkingCapital -24M 15M -38M 48M -10M -37M -49M -7M -8M -24M 103M -8M -10M 32M
otherNonCashItems 25M 10M 24M -36M 34M 33M 13M 170 000 2M 4M 11M 2M 4M 3M
netCashProvidedByOperatingActivities -117M -76M -359M -59M -82M -102M -288M -73M -67M -73M -84M -55M -159M -45M
investmentsInPropertyPlantAndEquipment -243 000 -3M -14M -2M -4M -7M -12M -827 000 -4M -5M -37M -9M -40M -6M
acquisitionsNet 0 0 277M 0 0 0 2M 0 2M 0 0 0 232M -3M
purchasesOfInvestments -2M -500 000 0 0 0 0 0 0 0 0 0 0 -301M 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 480 000 480 000 0 0 231M 62M 69M 0
otherInvestingActivites 0 -2M -3M -3M 0 398 000 0 0 0
netCashUsedForInvestingActivites -3M -6M -5M -4M -7M -347 000 -2M -5M 53M
debtRepayment -2M -2M -2M -26 000 -26 000 -24 000 -24 000 -24 000 -23 000
commonStockIssued 254M 103M 17M 262M 14M 54M 4M 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -993 000 -3M 2M 2M 14M 54M 0 2M 2M
netCashUsedProvidedByFinancingActivities 251M 98M 16M 263M 14M 54M 4M 2M 2M
effectOfForexChangesOnCash 2M 9M -3M 403 000 -118 000 -219 000 188 000 -115 000 181 000 -2000 -307 000 0 0 0
netChangeInCash 133M 25M 202M -40M 177M -95M -158M -20M -66M -77M 264M 780 000 28M 192M
cashAtEndOfPeriod 667M 534M 603M 436M 476M 300M 401M 397M 417M 482M 559M 465M 295M 267M
cashAtBeginningOfPeriod 534M 509M 401M 476M 300M 395M 559M 417M 482M 559M 295M 464M 267M 75M
operatingCashFlow -117M -76M -359M -59M -82M -102M -288M -73M -67M -73M -84M -55M -159M -45M
capitalExpenditure -243 000 -3M -14M -2M -4M -7M -12M -827 000 -4M -5M -37M -9M -40M -7M
freeCashFlow -118M -80M -373M -61M -86M -109M -300M -74M -71M -79M -121M -63M -198M -52M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-29 2023-02-27 2022-03-23 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -3M -597 000 -300 000 -232M -309 000
netCashProvidedByInvestingActivities 260M -10M 193M -272M -9M
netDebtIssuance -4M -766 000 -90 000 -13M 6M
longTermNetDebtIssuance -4M -766 000 -90 000 -13M 6M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 300M 128M 144M 463M 239M
netCommonStockIssuance 300M 128M 144M 463M 0
commonStockIssuance 300M 128M 144M 463M 0
netPreferredStockIssuance 0 0 0 0 239M
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 8M 13M 11M 8M 681 000
netCashProvidedByFinancingActivities 304M 140M 154M 459M 246M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 55 000 0 989 000

Earning call transcript

2025 q3
2025-11-05 ET (fiscal 2025 q3)
2025 q2
2025-08-05 ET (fiscal 2025 q2)
2025 q1
2025-05-05 ET (fiscal 2025 q1)
2024 q4
2025-02-28 ET (fiscal 2024 q4)
2024 q2
2024-08-09 ET (fiscal 2024 q2)
2024 q1
2024-05-09 ET (fiscal 2024 q1)
2023 q4
2024-02-27 ET (fiscal 2023 q4)

Press-releases

Show financial reports only

2026-08-05 ET
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
2026-08-04 ET
Recursion to Participate in Upcoming Investor Conferences
2026-07-31 ET
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
2026-07-29 ET
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
2026-06-16 ET
The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It
2026-06-02 ET
Recursion to Participate in Upcoming Investor Conferences
2026-05-29 ET
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
2026-05-06 10:30 ET
Recursion Reports First Quarter Financial Results and Provides Business Update
2026-04-30 20:30 ET
Recursion Announces Board Transition
2026-04-29 11:59 ET
Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6
2026-04-07 ET
Recursion to Participate in Upcoming Investor Conferences
2026-03-25 ET
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer
2026-02-25 ET
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2026-02-23 ET
Recursion To Be Featured in HighRes’ Lightning Talk at NVIDIA GTC
2026-02-23 ET
Recursion to Participate in Upcoming Investor Conferences
2026-02-18 13:30 ET
Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25
2026-02-12 12:59 ET
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
2026-01-06 ET
Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference
2025-12-08 ET
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
2025-12-08 ET
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
2025-12-01 ET
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025
2025-11-05 ET
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update
2025-11-05 ET
Recursion Announces CEO Transition Plan to Drive Next Phase of Growth
2025-11-04 ET
Recursion to Participate in Upcoming Investor Conferences
2025-10-28 ET
Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th
2025-08-27 ET
Recursion to Participate in Upcoming Investor Conferences
2025-08-05 ET
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update
2025-07-29 ET
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th
2025-07-08 ET
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
2025-06-06 ET
MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy
2025-05-30 ET
Recursion to Participate in Upcoming Investor Conferences
2025-05-06 ET
Recursion to Participate in Upcoming Investor Conferences
2025-05-05 ET
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update
2025-05-04 ET
Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden
2025-04-28 ET
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th
2025-04-22 ET
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
2025-04-16 ET
HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data
2025-04-09 ET
Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
2025-04-08 ET
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
2025-04-01 ET
Recursion to Participate in Upcoming Investor Conference
2025-03-18 ET
Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun
2025-02-28 ET
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
2025-02-24 ET
Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th
2025-02-19 ET
Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City
2025-02-18 ET
Altitude Lab Startups Raise $154M in Capital
2025-02-05 ET
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
2025-01-07 ET
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
2025-01-06 ET
Recursion to Present at 43rd Annual JP Morgan Healthcare Conference
2024-12-20 ET
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
2024-12-09 ET
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
2024-12-03 ET
Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
2024-11-20 ET
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
2024-11-20 ET
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
2024-11-13 ET
Recursion and Exscientia Shareholders Approve the Proposed Combination
2024-11-13 ET
Recursion and Exscientia Shareholders Approve the Proposed Combination
2024-11-12 ET
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
2024-11-06 21:15 ET
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
2024-10-30 12:22 ET
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
2024-10-22 12:00 ET
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
2024-10-02 12:00 ET
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
2024-09-03 12:00 ET
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
2024-09-03 12:00 ET
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
2024-08-08 11:39 ET
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
2024-08-08 11:39 ET
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
2024-08-08 11:30 ET
Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
2024-08-08 05:32 ET
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
2024-08-05 20:01 ET
Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
2024-06-27 02:07 ET
Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock
2024-06-26 20:06 ET
Recursion Announces Proposed Offering of Class A Common Stock
2024-06-24 13:00 ET
Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic Data
2024-06-03 13:00 ET
Recursion to Participate in Upcoming Investor Conferences
2024-05-29 19:27 ET
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
2024-05-24 20:30 ET
Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
2024-05-13 09:00 ET
Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
2024-05-09 20:01 ET
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
2024-05-02 12:00 ET
Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9
2024-05-01 12:01 ET
Recursion to Participate in Upcoming Investor Conferences
2024-04-30 12:00 ET
Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program
2024-04-16 12:00 ET
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
2024-04-16 12:00 ET
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
2024-04-02 12:00 ET
Recursion to Participate in Upcoming Investor Conference
2024-03-26 12:00 ET
Recursion Publishes Annual Environmental, Social and Governance Report
2024-03-11 08:00 ET
Recursion Announces Plans to Open New Office in London
2024-03-11 08:00 ET
Recursion Announces Plans to Open New Office in London
2024-03-01 19:58 ET
Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community
2024-03-01 12:59 ET
Recursion to Participate in Upcoming Investor Conferences
2024-02-27 21:05 ET
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
2024-02-20 12:59 ET
Recursion to Host Public L(earnings) Call on February 27
2024-01-24 14:00 ET
Altitude Lab Startups Raise Over $120M in Capital
2024-01-24 ET
Altitude Lab Startups Raise Over $120M in Capital
2024-01-08 15:59 ET
Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference
2024-01-04 12:59 ET
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
2024-01-04 12:59 ET
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
2024-01-03 13:00 ET
Recursion to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
2023-12-20 12:59 ET
Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry
2023-11-09 18:48 ET
Bayer and Recursion focus research collaboration on Oncology
2023-11-09 14:41 ET
Bayer and Recursion Focus Research Collaboration on Oncology
2023-11-09 13:01 ET
Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
2023-11-09 13:01 ET
Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
2023-11-09 12:58 ET
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results
2023-11-02 12:05 ET
Recursion to Participate in Upcoming Investor Conference
2023-09-05 20:30 ET
Recursion to Participate in Upcoming Investor Conferences
2023-09-05 11:59 ET
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
2023-08-08 12:00 ET
Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds
2023-08-08 11:58 ET
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
2023-08-01 12:30 ET
Recursion to Participate in Upcoming Investor Conference
2023-07-26 22:58 ET
Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships
2023-07-12 12:30 ET
Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
2023-07-12 12:30 ET
Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
2023-07-12 ET
Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
2023-07-12 ET
Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
2023-06-26 15:48 ET
Recursion Celebrates Opening of Its Canadian Headquarters in Toronto with Government Officials and the Biotech Ecosystem
2023-06-13 12:00 ET
Recursion’s Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully Enrolled
2023-06-01 12:30 ET
Recursion to Participate in Upcoming Investor Conferences
2023-05-25 20:00 ET
Altitude Lab Relocates to Gateway’s BioHive Hub
2023-05-16 12:30 ET
Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer
2023-05-08 12:14 ET
Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results
2023-05-08 11:59 ET
Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities
2023-05-08 11:59 ET
Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities
2023-05-02 12:30 ET
Recursion to Participate in Upcoming Investor Conferences
2023-04-03 12:30 ET
Recursion to Participate in Upcoming Investor Conference
2023-03-28 20:14 ET
Recursion Publishes Second Annual Environmental, Social and Governance Report
2023-03-01 13:00 ET
Recursion to Participate in Upcoming Investor Conferences
2023-02-01 13:01 ET
Recursion to Participate in Upcoming Investor Conference
2023-01-26 13:30 ET
Recursion Releases MolRec, a Compound Intelligence Tool for Drug Discovery, Alongside the Largest of Its Kind Open-Source Dataset During First R&D Day
2022-12-20 12:55 ET
Recursion to Participate in Upcoming Investor Conferences
2022-11-08 21:30 ET
Recursion Provides Business Updates and Reports Third Quarter 2022 Financial Results
2022-11-02 11:59 ET
Recursion to Participate in Upcoming Investor Conferences
2022-10-25 12:00 ET
Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB
2022-09-13 11:59 ET
Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022
2022-09-01 11:55 ET
Recursion to Participate in Upcoming Investor Conferences
2022-08-18 11:55 ET
Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum
2022-08-09 20:15 ET
Recursion Provides Business Updates and Reports Second Quarter 2022 Financial Results
2022-08-02 11:55 ET
Recursion to Participate in Upcoming Investor Conference
2022-07-21 11:55 ET
Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
2022-06-20 11:55 ET
Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at Children's Tumor Foundation NF Conference
2022-06-02 11:55 ET
Recursion to Participate in Upcoming Investor Conferences
2022-05-10 20:29 ET
Recursion Provides Business Updates and Reports First Quarter 2022 Financial Results
2022-05-02 11:55 ET
Recursion to Participate in Upcoming Investor Conference
2022-04-11 11:55 ET
Recursion is Granted Fast Track Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
2022-03-31 11:55 ET
Recursion to Participate in Upcoming Investor Conferences
2022-03-30 11:55 ET
Altitude Lab Announces First Cohort of Startups Close Over $50M in Seed Capital
2022-03-24 11:55 ET
Recursion Publishes First Environmental, Social and Governance (ESG) Report
2022-03-23 11:55 ET
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results
2022-03-18 11:55 ET
Recursion Announces Enrollment of First Patient in Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation
2022-03-03 12:55 ET
Recursion Provides Updated Guidance on Clinical Trial Starts
2022-03-02 13:47 ET
Recursion to Participate in Upcoming Investor Conferences
2022-02-08 12:55 ET
Recursion to Participate in Upcoming Investor Conferences
2021-12-07 12:55 ET
Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology, Advancing Novel Medicines to Patients Using Machine Learning and High Content Screening Methods at Scale to Map Complex Biology
2021-12-06 12:55 ET
Recursion and Bayer Expand Fibrosis Collaboration to Include Inferential Search Capabilities
2021-11-30 12:55 ET
Recursion Enhances its Leadership Team and Deepens Focus on Neuroscience with Three Senior Appointments
2021-11-10 12:55 ET
Recursion Provides Business Updates and Reports Third Quarter 2021 Financials
2021-10-07 11:55 ET
Recursion is Granted FDA Fast Track Designation for REC-2282 for the Potential Treatment of NF2-Mutated Meningiomas
2021-09-29 12:54 ET
Recursion is Granted Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
2021-08-13 11:55 ET
Recursion Reports Second Quarter 2021 Financials and Provides Business Updates
2021-07-13 11:55 ET
Recursion Announces Therapeutics Advisory Board, Chaired by Joseph Miletich, MD, PhD
2021-07-12 20:41 ET
Recursion Opens Child Care Center to Support Employees
2021-07-01 12:54 ET
Recursion Signs Lease With Vestar for an Additional 100,000 sf of Space at the Gateway in Downtown Salt Lake City
2021-06-23 12:53 ET
Recursion Announces Multi-Year Collaboration with Mila for Tech-Enabled Drug Discovery
2021-06-15 12:54 ET
Recursion Announces its First Major Multidisciplinary Expansion, in Toronto, to Further Tech-Enabled Drug Discovery
2021-05-25 12:25 ET
Recursion Announces First Internally-Developed NCE Advanced to IND-Enabling Studies to Potentially Treat Clostridium difficile Colitis
2021-05-12 12:45 ET
Recursion Reports First Quarter 2021 Financials and Provides Business Updates
2021-04-21 12:00 ET
Recursion Pharmaceuticals Announces Closing of Initial Public Offering
2021-04-16 04:13 ET
Recursion Pharmaceuticals Announces Pricing of Initial Public Offering

SEC forms

Show financial reports only

SEC form 10
2026-08-05 10:32 ET
Recursion Pharmaceuticals, Inc. reported for 2026 q2
SEC form 8
2026-08-05 10:31 ET
Recursion Pharmaceuticals, Inc. published news for 2026 q2
SEC form 8
2026-08-05 10:31 ET
Recursion Pharmaceuticals, Inc. reported for 2026 q2
SEC form 8
2026-08-05 10:31 ET
Recursion Pharmaceuticals, Inc. published news for 2026 q2
SEC form 8
2026-08-05 10:31 ET
Recursion Pharmaceuticals, Inc. published news for 2026 q2
SEC form 10
2026-05-06 10:32 ET
Recursion Pharmaceuticals, Inc. reported for 2026 q1
SEC form 8
2026-05-06 10:31 ET
Recursion Pharmaceuticals, Inc. published news for 2026 q1
SEC form 8
2026-05-06 10:31 ET
Recursion Pharmaceuticals, Inc. reported for 2026 q1
SEC form 8
2026-05-06 10:31 ET
Recursion Pharmaceuticals, Inc. published news for 2026 q1
SEC form 10
2026-02-25 06:33 ET
Recursion Pharmaceuticals, Inc. reported for 2025 q4
SEC form 8
2026-02-25 06:31 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q4
SEC form 8
2026-02-25 06:31 ET
Recursion Pharmaceuticals, Inc. reported for 2025 q4
SEC form 8
2026-02-25 06:31 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q4
SEC form 8
2026-01-12 13:21 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q4
SEC form 8
2026-01-12 13:21 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q4
SEC form 8
2025-12-08 07:31 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q3
SEC form 8
2025-12-08 07:31 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q3
SEC form 8
2025-12-08 07:31 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q3
SEC form 8
2025-11-26 13:12 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q3
SEC form 8
2025-11-26 13:12 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q3
SEC form 10
2025-11-05 11:40 ET
Recursion Pharmaceuticals, Inc. reported for 2025 q3
SEC form 8
2025-11-05 11:37 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q3
SEC form 8
2025-11-05 11:37 ET
Recursion Pharmaceuticals, Inc. reported for 2025 q3
SEC form 8
2025-11-05 11:37 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q3
SEC form 8
2025-11-05 11:37 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q3
SEC form 8
2025-11-05 11:37 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q3
SEC form 8
2025-08-29 20:28 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q2
SEC form 8
2025-08-29 20:28 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q2
SEC form 10
2025-08-05 10:33 ET
Recursion Pharmaceuticals, Inc. reported for 2025 q2
SEC form 8
2025-08-05 10:31 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q2
SEC form 8
2025-08-05 10:31 ET
Recursion Pharmaceuticals, Inc. reported for 2025 q2
SEC form 8
2025-08-05 10:31 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q2
SEC form 8
2025-08-05 10:31 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q2
SEC form 8
2025-06-10 10:04 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q1
SEC form 8
2025-06-10 10:04 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q1
SEC form 8
2025-05-09 21:27 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q1
SEC form 8
2025-05-09 21:27 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q1
SEC form 10
2025-05-05 10:02 ET
Recursion Pharmaceuticals, Inc. reported for 2025 q1
SEC form 10
2025-05-05 00:00 ET
Recursion Pharmaceuticals, Inc. reported for 2025 q1
SEC form 8
2025-05-05 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q1
SEC form 8
2025-05-05 00:00 ET
Recursion Pharmaceuticals, Inc. reported for 2025 q1
SEC form 8
2025-05-05 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2025 q1
SEC form 10
2025-02-28 06:33 ET
Recursion Pharmaceuticals, Inc. reported for 2024 q4
SEC form 8
2025-02-28 06:31 ET
Recursion Pharmaceuticals, Inc. published news for 2024 q4
SEC form 8
2025-02-28 06:31 ET
Recursion Pharmaceuticals, Inc. reported for 2024 q4
SEC form 8
2025-02-28 06:31 ET
Recursion Pharmaceuticals, Inc. published news for 2024 q4
SEC form 8
2025-02-28 06:31 ET
Recursion Pharmaceuticals, Inc. published news for 2024 q4
SEC form 10
2025-02-28 00:00 ET
Recursion Pharmaceuticals, Inc. reported for 2024 q4
SEC form 10
2024-11-06 16:18 ET
Recursion Pharmaceuticals, Inc. published news for 2024 q3
SEC form 8
2024-11-06 16:17 ET
Recursion Pharmaceuticals, Inc. published news for 2024 q3
SEC form 8
2024-11-06 16:17 ET
Recursion Pharmaceuticals, Inc. published news for 2024 q3
SEC form 8
2024-11-06 16:17 ET
Recursion Pharmaceuticals, Inc. published news for 2024 q3
SEC form 10
2024-08-08 08:09 ET
Recursion Pharmaceuticals, Inc. reported for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Recursion Pharmaceuticals, Inc. reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2024 q1
SEC form 10
2024-02-29 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q4
SEC form 8
2024-02-27 16:09 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q4
SEC form 8
2024-02-27 16:09 ET
Recursion Pharmaceuticals, Inc. reported for 2023 q4
SEC form 8
2024-02-27 16:09 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q4
SEC form 8
2024-02-27 16:09 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q4
SEC form 10
2023-11-09 08:08 ET
Recursion Pharmaceuticals, Inc. reported for 2023 q3
SEC form 10
2023-11-09 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q3
SEC form 10
2023-08-08 08:08 ET
Recursion Pharmaceuticals, Inc. reported for 2023 q2
SEC form 6
2023-08-08 08:03 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q2
SEC form 6
2023-07-12 08:32 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q2
SEC form 6
2023-06-20 17:09 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q1
SEC form 6
2023-06-13 08:14 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q1
SEC form 10
2023-05-08 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q1
SEC form 8
2023-05-08 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2023 q1
SEC form 6
2023-03-10 16:06 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q4
SEC form 10
2023-02-27 16:44 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q4
SEC form 6
2023-02-27 16:35 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q4
SEC form 10
2023-02-27 00:00 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q4
SEC form 8
2023-02-27 00:00 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q4
SEC form 6
2023-01-25 07:02 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q4
SEC form 6
2023-01-13 17:00 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q4
SEC form 6
2023-01-10 08:01 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q4
SEC form 10
2022-11-08 16:35 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q3
SEC form 6
2022-11-08 16:31 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q3
SEC form 6
2022-10-25 08:04 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q3
SEC form 6
2022-09-13 08:01 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q2
SEC form 10
2022-08-09 16:20 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q2
SEC form 6
2022-08-09 16:17 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q2
SEC form 6
2022-06-21 08:04 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q1
SEC form 6
2022-06-16 16:31 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q1
SEC form 6
2022-06-09 17:00 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q1
SEC form 10
2022-05-10 16:38 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q1
SEC form 6
2022-05-10 16:34 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q1
SEC form 10
2022-05-10 00:00 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q1
SEC form 8
2022-05-10 00:00 ET
Recursion Pharmaceuticals, Inc. reported for 2022 q1
SEC form 6
2022-04-28 16:01 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q1
SEC form 6
2022-04-11 07:55 ET
Recursion Pharmaceuticals, Inc. published news for 2022 q1
SEC form 10
2022-03-23 08:01 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q4
SEC form 6
2022-03-23 07:56 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q4
SEC form 10
2022-03-23 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q4
SEC form 8
2022-03-23 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q4
SEC form 6
2022-03-18 08:02 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q4
SEC form 6
2022-03-03 07:57 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q4
SEC form 6
2022-01-10 06:20 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q4
SEC form 6
2021-12-07 07:57 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-12-06 07:55 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q3
SEC form 10
2021-11-10 07:57 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-11-10 07:55 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q3
SEC form 8
2021-11-10 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-07 08:01 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-09-09 08:01 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q2
SEC form 10
2021-08-13 07:57 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q2
SEC form 6
2021-08-13 07:55 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q2
SEC form 10
2021-08-13 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q2
SEC form 8
2021-08-13 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q2
SEC form 6
2021-07-13 08:18 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q2
SEC form 10
2021-05-12 08:47 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q1
SEC form 6
2021-05-12 08:46 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q1
SEC form 10
2021-05-12 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q1
SEC form 8
2021-05-12 00:00 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q1
SEC form 6
2021-04-21 09:08 ET
Recursion Pharmaceuticals, Inc. published news for 2021 q1